COMPANY PROFILE

Amlogenyx

Amlogenyx, a subsidiary of Ultragenyx Pharmaceutical, Inc., focuses on researching and developing new gene therapies for Alzheimer’s disease and other amyloid-related conditions

Somerville, United StatesFounded 2023Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Total funding $10–50M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2023
Headquarters: Somerville, United States
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Medical Research, Research and Development, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Aug 2024	$14M	$56M	Ultragenyx Pharmaceutical · GordonMD Global Investment	↗
SPINOUT✓Other financing	Oct 2023	$0	—	Ultragenyx Pharmaceutical	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PRProfionicsInnovative diagnostic solutions leveraging biomarkers and AI to rapidly detect and treat sepsis	Stevenage, United Kingdom	Operational	3	—	—
CBCurve BiosciencesUnlocking the right data to help patients with chronic disease on their decades-long journey	Mountain View, United States	Operational
VTVasa TherapeuticsPrecision medicine for heart failure and healthy aging	Encinitas, United States	Operational
NSNeuracle ScienceRetrocious nervous disorders, such as Alzheimer's disease, have become a major problem in modern society as well as the entry into the aging business	Seoul, South Korea	Operational
GBGennao BioGennao Bio is pioneering the development of targeted nucleic acid therapeutics using its unique, non-viral GMAB platform technology	Hopewell, United States	Operational
YBY BiologicsY-Biologics is Korea's leading R&D biotech company specializing in antibody drug development	Daejeon, South Korea	Operational
IMImcyseSpecific immunotherapies for severe autoimmune diseases	Liège, Belgium	Operational
NTNxera Pharma UK \| Heptares TherapeuticsDevelops novel, small-molecule drugs for G-protein-coupled receptors	Great Abington, United Kingdom	Acquired